Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices
Chapter 12 - Solid Lipid Nanoparticles in Drug Delivery: Opportunities and Challenges
References (0)
Cited by (23)
A novel lipophenol quercetin derivative to prevent macular degeneration: Intravenous and oral formulations for preclinical pharmacological evaluation
2024, International Journal of PharmaceuticsA state-of-the-art review on solid lipid nanoparticles as a nanovaccines delivery system
2023, Journal of Drug Delivery Science and TechnologyEmpowering treatment strategies for pancreatic cancer by employing lipid nanoparticle-driven drug delivery
2023, Recent Advances in Nanocarriers for Pancreatic Cancer TherapyNanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease
2022, Journal of Controlled ReleaseCitation Excerpt :They are the lipid based nanocarriers that are synthesized from solid lipids or mixtures in an aqueous dispersion at a concentration ranging from 0.1 %w/w to 30%w/w and the formulation is stabilized by adding emulsifier at a concentration of 0.5%w/w to 5%w/w and SLNs are solid at body temperature [170,185–190]. Because of their potential to transport and solubilize lipophilic drug molecules, lipid-based systems such as SLNs have piqued interest in drug formulation and development [191]. The formulation of SLNs includes homogenization, microemulsion, solvent diffusion-evaporation techniques [192].
Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy
2021, Advanced Drug Delivery ReviewsCitation Excerpt :These SLN nanoparticles ensure higher drug stability and prolonged release because of their crystalline structure. On the other hand, the high crystallinity of solid lipid nanoparticles can cause limited drug loading and drug expulsion due to polymorphic transitions of solid lipid [139]. Hence many improved systems such as oil-loaded SLNs (nanostructured lipid carriers, NLC), and calixarene-based SLNs were developed and characterized to resolve these issues.
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
2021, Acta Pharmaceutica Sinica BCitation Excerpt :From the 37 approved nasal medicines, 1 is a TrueTear™ device for neuropathic corneal pain, 2 contain influenza vaccines and 34 contain different drugs, being midazolam, ketamine and dexmedetomidine the most prevalent. However, to our knowledge, there are no nasal formulations of SLNs, NLCs and NEs marketed, although the use of these nanocarriers has been studied to improve the drug deliver through other routes of administration, such as oral, parenteral, cutaneous, ocular, rectal and pulmonary, and for cosmetics45,48,96. Despite the several investigations that have been carried out, only cosmetic products with SLNs and NLCs have been approved37,41,42,97,98.